TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Options calculator
  • Leaderboards
  • Insider trades
  • 13F funds
  • Groups
  • Trending
  • News

More

  • Pricing
  • Feedback
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback
Home›RGEN›Financials
Annual statements · SEC XBRL · FY2016 – FY2025

REPLIGEN CORP (RGEN) financials

Income statement

REPLIGEN CORP (RGEN) income statement, annual, from SEC filings
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue$105M$141M$194M$270M$366M$671M$802M$632M$634M$738M
Revenue growth—35.1%37.4%39.3%35.5%83.1%19.5%-21.1%0.3%16.4%
Operating income$16.0M$14.0M$26.0M$36.1M$69.8M$167M$225M$47.7M-$35.1M$55.2M
Operating margin15.3%9.9%13.4%13.4%19.1%24.9%28.0%7.5%-5.5%7.5%
Net income$11.7M$28.4M$16.6M$21.4M$59.9M$128M$186M$35.6M-$25.5M$48.9M
Net margin11.2%20.1%8.6%7.9%16.4%19.1%23.2%5.6%-4.0%6.6%
EPS (diluted)$0.34$0.72$0.37$0.44$1.11$2.24$3.24$0.63-$0.46$0.86

Cash flow

REPLIGEN CORP (RGEN) cash flow, annual, from SEC filings
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow$7.52M$17.5M$32.8M$67.2M$62.6M$119M$172M$114M$175M$117M
Capital expenditures$4.33M$5.45M$10.6M$18.5M$22.5M$67.1M$84.8M$36.2M$25.7M$23.5M
Free cash flow$3.20M$12.0M$22.1M$48.7M$40.2M$51.9M$87.2M$77.7M$150M$93.9M
Share buybacks—————$0.00$0.00$14.4M$0.00$0.00

Balance sheet

REPLIGEN CORP (RGEN) balance sheet, annual, from SEC filings
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash & equivalents$122M$174M$194M$528M$717M$604M$523M$751M$757M$566M
Total assets$289M$744M$775M$1.40B$1.90B$2.36B$2.52B$2.83B$2.83B$2.95B
Total liabilities—$152M$159M$340M$374M$608M$614M$866M$857M$844M
Long-term debt————————$526M$542M
Shareholders' equity$169M$592M$616M$1.06B$1.53B$1.75B$1.91B$1.96B$1.97B$2.11B
Retained earnings-$59.9M-$31.5M-$677K$5.84M$65.8M$194M$397M$433M$407M$456M
Shares (wtd avg diluted)34.1B39.1M45.5M49.2M53.9B57.3B57.5B56.4B55.9B56.6B

Every figure is extracted from REPLIGEN CORP’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.

Common questions

What is REPLIGEN CORP's annual revenue?
REPLIGEN CORP (RGEN) reported $738M of revenue for fiscal year 2025 — up 16.4% from $634M in FY2024, per its annual report filed with the SEC.
Is REPLIGEN CORP profitable?
Yes — RGEN earned $48.9M of net income in FY2025, a 6.6% net margin, per SEC filings.
What is REPLIGEN CORP's free cash flow?
$93.9M in FY2025 (operating cash flow $117M minus $23.5M of capital expenditures), from the SEC cash-flow statement.
Does RGEN pay a dividend?
REPLIGEN CORP reported no cash dividends paid in FY2025, per its SEC cash-flow statement.
Full RGEN analysis — verdict, score & filings →Is RGEN a buy? →

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.